15:36 , Jul 27, 2018 |  BC Week In Review  |  Company News

Sobi grabs Emapalumab, anticipates 2018 approval

Swedish Orphan Biovitrum AB (SSE:SOBI) received exclusive, worldwide rights from Novimmune S.A. (Plan-les-Ouates, Switzerland) to hematology candidate emapalumab (NI-0501). Novimmune will receive SEK450 million ($50.8 million) up front in cash, plus SEK3.6 billion ($406.5 million) in...
22:11 , Jul 20, 2018 |  BC Extra  |  Company News

Sobi grabs emapalumab, anticipates 2018 approval

Swedish Orphan Biovitrum AB (SSE:SOBI) received exclusive, worldwide rights from Novimmune S.A. (Plan-les-Ouates, Switzerland) to hematology candidate emapalumab (NI-0501). Novimmune will receive SEK450 million ($50.8 million) up front in cash, plus SEK3.6 billion ($406.5 million) in...
02:56 , May 4, 2018 |  BC Innovations  |  Targets & Mechanisms

Solid hopes for T cell bispecifics

As next-generation T cell bispecifics hit the clinic, demonstrating efficacy in solid tumors could earn them a place in the immuno-oncology tool kit alongside CAR T cells and checkpoint inhibitors. T cell bispecific antibodies bring activated...
22:52 , Apr 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cancer; cervical cancer; gastric cancer; lung cancer; pancreatic cancer Cell culture and mouse studies suggest three mesothelin-targeting chimeric immunotoxins could help treat mesothelin-expressing cancers. The three immunotoxins consist of the variable region a mouse mesothelin-targeting...
15:46 , Mar 28, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Cell therapy CAR T cells engineered to express IL-7 and CCL19 could enhance the efficacy of T cell therapies for cancer. The method involves engineering solid tumor antigen-targeting CAR T cells, dubbed proliferation-inducing and migration-enhancing...
17:48 , Mar 23, 2018 |  BC Week In Review  |  Financial News

TCR2 raises $125M series B

TCR2 Therapeutics Inc. (Cambridge, Mass.) raised an untranched $125 million series B round on March 21 led by 6 Dimensions Capital and Curative Ventures and joined by fellow new investors Redmile Group, ArrowMark Partners, Hillhouse...
23:26 , Mar 21, 2018 |  BioCentury  |  Finance

Seeking domestic partners

The syndicate behind TCR2 Therapeutics Inc.’s $125 million series B round includes a bevy of Chinese investors who could provide access to development and manufacturing partners in China. 6 Dimensions Capital and Curative Ventures led the...
12:00 , Mar 21, 2018 |  BC Extra  |  Financial News

TCR2 raises $125M series B

TCR2 Therapeutics Inc. (Cambridge, Mass.) raised an untranched $125 million series B round led by 6 Dimensions Capital and Curative Ventures and joined by fellow new investors Redmile Group, ArrowMark Partners, Hillhouse Capital, MiraeAsset Financial...
00:50 , Mar 7, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Chronic myelogenous leukemia (CML), mesothelioma; pancreatic cancer Cell culture and mouse studies suggest CD4/DPP-4-positive, mesothelin-targeting CAR T cells could help treat CML, mesothelioma and pancreatic ductal adenocarcinoma (PDAC). In a human mesothelin-expressing CML cell line,...
02:05 , Dec 14, 2017 |  BC Week In Review  |  Clinical News

Aduro discontinues development of CRS-207

Aduro Biotech Inc. (NASDAQ:ADRO) said it will discontinue development of CRS-207 based on "insufficient clinical activity" in Phase I/II trials of the candidate to treat mesothelioma and ovarian cancer. Aduro said it will now focus...